Cabozantinib (XL184, BMS-907351) CAS 849217-68-1

【Product name】: Cabozantinib (XL184, BMS-907351)

【CAS No.】:849217-68-1

【Appearance】: White to off-white crystalline powder

【Purity】: ≥99%， HPLC available

【Storage】：Store at room temperature, sealed and protected from light

【Description】: Cabozantinib is a targeted drug for the treatment of cancer, but it has not yet been approved for marketing in my country. Cabozantinib, codenamed XL184, is a multi-target small molecule tyrosine kinase inhibitor, including nine targets: MET, VEGFR1 2 3, ROS1, RET, AXL, NTRK, and KIT. Mainly anti-angiogenesis, but also taking into account targets such as RET and MET. It has been confirmed that it has good therapeutic effects in various solid tumors such as kidney cancer, thyroid cancer, liver cancer, soft tissue sarcoma, non-small cell lung cancer, prostate cancer, breast cancer, ovarian cancer, intestinal cancer, etc., and has a good control effect on bone metastasis. Especially outstanding.